A single-center, open-label, two-part, one-sequence crossover study to investigate the effect of cyclosporine and rifampicin on the pharmacokinetics of macitentan in healthy male subjects

Trial Profile

A single-center, open-label, two-part, one-sequence crossover study to investigate the effect of cyclosporine and rifampicin on the pharmacokinetics of macitentan in healthy male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Macitentan (Primary) ; Ciclosporin; Rifampicin
  • Indications Atopic dermatitis; Eisenmenger complex; Glioblastoma; Idiopathic pulmonary fibrosis; Psoriasis; Pulmonary arterial hypertension; Rheumatoid arthritis; Skin ulcer; Transplant rejection; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top